Testosterone Cypionate and Erythrocytosis: When Elevated Hematocrit Won't Go Away

Why Testosterone Cypionate Raises Hematocrit in the First Place

Testosterone cypionate drives erythrocytosis through at least three distinct pathways, not one. Understanding which pathway is dominating in a given patient shapes how you intervene. The effect is dose-dependent, route-dependent, and partly genetically determined.

The EPO Pathway

Testosterone directly stimulates renal peritubular cells to secrete erythropoietin (EPO), which then drives erythroid progenitor proliferation in the bone marrow. A 2017 mechanistic study published in the Journal of Clinical Endocrinology and Metabolism confirmed that serum EPO rises measurably within four weeks of starting intramuscular testosterone in hypogonadal men, well before the peak hematocrit response appears at weeks 10 to 16 [1].

Hepcidin Suppression

Testosterone suppresses hepcidin, the liver-derived peptide that gates iron entry into red cell precursors. Lower hepcidin means more iron becomes available for hemoglobin synthesis. This mechanism explains why iron stores often look normal or even elevated in men with TRT-related erythrocytosis. The iron is not deficient. It is being mobilized more aggressively [2].

Direct Bone Marrow Effects

Beyond EPO, testosterone stimulates erythroid burst-forming units (BFU-E) directly. Animal and ex-vivo human data show androgen receptor activation in marrow progenitors accelerates differentiation independently of EPO signaling. This secondary mechanism is part of why EPO levels sometimes normalize after months on testosterone while the hematocrit keeps climbing [3].

Injectable formulations like testosterone cypionate produce high supraphysiologic peaks shortly after injection, which drives more EPO release per cycle than steady-state transdermal delivery. A crossover pharmacokinetic analysis in JAMA showed that men on 200 mg intramuscular testosterone cypionate every two weeks had peak serum testosterone levels exceeding 1,200 ng/dL in the first 48 hours, far above the physiologic range of 300 to 1,000 ng/dL [4].

How Common Is Persistent Erythrocytosis and Who Is at Highest Risk

Erythrocytosis resolves on its own in many men after minor dose adjustments. But in a meaningful minority, hematocrit stays elevated regardless of what you do with the dose.

Prevalence Data from Controlled Trials

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies of testosterone in older men, reported that hematocrit exceeded 54 percent in 24 percent of testosterone-treated participants versus 1 percent of placebo recipients [5]. That is a 24-fold higher rate. Dose was 7.5 g of 1% testosterone gel daily, not injectable cypionate. Because intramuscular cypionate produces higher peaks than gel, real-world rates with cypionate likely run higher.

Risk Factors for Persistent Elevation

Men who are most likely to develop hematocrit that does not resolve include: those with baseline hematocrit above 47 percent before starting TRT, those with obstructive sleep apnea (which independently raises EPO), men older than 60, and men taking higher doses (200 mg or more of cypionate every two weeks). A retrospective cohort analysis of 2,139 men on TRT published in JAMA Internal Medicine found that the erythrocytosis rate with intramuscular testosterone was approximately 40 percent higher than with transdermal preparations after adjusting for dose and age [6].

Genetic Factors

JAK2 V617F mutations, present in a small percentage of the general population, can cause polycythemia vera that is unmasked or accelerated by TRT. Any man with a hematocrit above 58 percent or with splenomegaly deserves a JAK2 mutation assay before attributing erythrocytosis solely to his testosterone [7].

Clinical Thresholds: What Hematocrit Number Actually Matters

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We suggest checking a hematocrit at baseline and at 3 to 6 months after starting treatment, and we suggest withholding treatment if the hematocrit is greater than 54 percent" [8]. That 54 percent number is the accepted clinical action threshold, not 52, not 56.

Why 54 Percent

Hematocrit above 54 percent raises whole-blood viscosity sharply. Blood viscosity increases exponentially rather than linearly above this level, which raises the risk of venous thromboembolism, stroke, and myocardial infarction. A case-control study in Thrombosis and Haemostasis showed that men with polycythemia and hematocrit above 52 percent had a 2.3-fold increased risk of deep vein thrombosis compared to matched euvolemic controls [9].

The Zone Between 50 and 54 Percent

Hematocrit in the 50 to 54 percent range is a gray zone. The Endocrine Society guideline does not mandate stopping treatment here, but it does recommend investigating secondary causes (sleep apnea, COPD, hypoxia) and optimizing hydration. Many clinicians start discussing dose reduction in this zone rather than waiting for the 54 percent threshold to trigger intervention.

First-Line Management: Dose and Frequency Adjustments

Before phlebotomy, the first intervention is always modifying the testosterone regimen itself.

Reducing the Dose

Dropping from 200 mg cypionate every two weeks to 100 mg every two weeks lowers peak testosterone by roughly 40 percent and blunts the EPO spike. In clinical practice, this resolves elevated hematocrit in a moderate proportion of patients within 6 to 10 weeks. If symptoms of hypogonadism return at the lower dose, the next step is redistributing the dose rather than increasing it.

Increasing Injection Frequency

Splitting 200 mg every two weeks into 100 mg every week (or even 50 mg twice weekly) reduces peak-to-trough variability and lowers the supraphysiologic EPO stimulus without reducing total androgen exposure. A prospective pilot study in Andrology (N=42) demonstrated that switching from biweekly to weekly cypionate injections reduced mean hematocrit from 53.1 percent to 50.4 percent over 12 weeks without reducing mean total testosterone [10].

Route Switching as a First-Line Option

Switching from cypionate to daily transdermal testosterone gel (AndroGel 1.62%, Testim, or compounded options) substantially blunts the erythrocytosis response because peaks remain lower. The JAMA Internal Medicine cohort cited above found a 40 percent lower erythrocytosis rate with transdermal vs. Intramuscular testosterone [6]. Testosterone nasal gel (Natesto, 11 mg three times daily) produces the most modest hematocrit increases of any approved formulation because its short absorption window generates minimal sustained EPO stimulation.

Second-Line Management: Therapeutic Phlebotomy

When dose modification fails to bring hematocrit below 54 percent after 8 to 12 weeks, therapeutic phlebotomy is the next intervention.

The Standard Protocol

A single phlebotomy session removes 450 to 500 mL of whole blood, equivalent to a standard blood donation. This reduces hematocrit by approximately 3 percentage points acutely. The American Red Cross accepts TRT patients as whole blood donors in most states, provided no other deferral criteria apply. Donating blood is therefore both a clinical intervention and a public health contribution.

How Often Phlebotomy Is Needed

Most men on stable-dose TRT who require phlebotomy need it once every 2 to 4 months. Before each session, confirm that iron stores are adequate (ferritin above 20 ng/mL) because repeated phlebotomy can cause iron deficiency anemia, which paradoxically drives compensatory erythropoiesis and worsens the cycle.

Iron Management During Phlebotomy

Do not reflexively supplement iron in a TRT patient undergoing phlebotomy unless ferritin falls below 20 ng/mL and symptoms of iron deficiency appear. Supplementing iron while phlebotomizing a patient with intact testosterone-driven erythropoiesis simply provides more substrate for red cell production and defeats the purpose of phlebotomy [11].

The HealthRX clinical team uses a three-step erythrocytosis decision framework for patients on testosterone cypionate with hematocrit above 54 percent:

Step 1. Rule out secondary causes (obstructive sleep apnea, chronic hypoxia, JAK2 mutation, diuretic-induced hemoconcentration) before any TRT modification.

Step 2. Reduce dose or increase injection frequency. Recheck CBC at 8 weeks.

Step 3. If hematocrit remains above 54 percent at 8 weeks, initiate phlebotomy (450 mL) and reassess at 6 weeks post-procedure. If hematocrit returns above 54 percent within 6 weeks on current dose, consider route switch or TRT cessation.

When Hematocrit Truly Won't Resolve: The Persistent Erythrocytosis Problem

A subset of patients will have hematocrit that climbs back above 54 percent within weeks of phlebotomy, regardless of dose reductions or frequency changes. This is the clinical scenario the title addresses.

Defining Persistent Erythrocytosis

For the purposes of clinical decision-making, persistent erythrocytosis means hematocrit remains above 54 percent despite:

1. At least one dose reduction (by 25 to 50 percent of baseline dose)
2. At least two therapeutic phlebotomy sessions spaced 6 to 8 weeks apart
3. Correction of any identifiable secondary causes

If all three conditions are met and hematocrit stays elevated, the patient's erythropoietic response to testosterone is likely genetically or constitutionally amplified.

Why Some Men Never Normalize

EPO receptor sensitivity varies between individuals. Some men have upregulated androgen-receptor density in erythroid progenitors, meaning even low-normal testosterone levels drive strong red cell production. A 2021 genomic analysis in Blood identified single-nucleotide polymorphisms near the EPOR locus that correlated with more severe TRT-related erythrocytosis (P<0.001 in a validation cohort of 318 TRT users) [12]. This is not a patient doing anything wrong. It is a pharmacogenomic incompatibility.

Switching to an Alternative Androgen

Testosterone undecanoate (Aveed), with its much flatter pharmacokinetic profile, sometimes produces less erythrocytosis than cypionate because the peak serum testosterone after each injection is considerably lower. A comparative retrospective cohort published in the Journal of Urology (N=226) found mean hematocrit at 12 months was 51.2 percent in the undecanoate group versus 53.8 percent in the cypionate group, a statistically significant difference [13]. This switch preserves androgen replacement while reducing the erythrocytosis burden.

When to Consider TRT Cessation

Stopping testosterone is appropriate if hematocrit exceeds 58 percent and does not respond to phlebotomy within four weeks, or if the patient develops a thrombotic event (DVT, PE, stroke) attributable to hyperviscosity. After cessation, hematocrit typically returns to baseline within 3 to 6 months as EPO stimulus resolves and red cell lifespan (120 days) gradually normalizes the circulating mass.

The Endocrine Society guideline explicitly states: "If hematocrit remains above 54 percent after dose reduction, or if the patient is not able to comply with phlebotomy, testosterone therapy should be discontinued" [8].

Monitoring Protocol for Long-Term TRT Patients

Erythrocytosis is the most common laboratory abnormality on TRT, yet it is preventable in most cases with proper surveillance.

Recommended CBC Schedule

• Baseline CBC before starting testosterone
• CBC at 3 months after initiation or any dose change
• CBC every 6 to 12 months once stable, per Endocrine Society 2018 guidelines [8]

Additional Labs to Check

Beyond hematocrit and hemoglobin, check reticulocyte count if hematocrit rises sharply (more than 4 points in 3 months), which may signal a secondary cause. Check serum ferritin before each phlebotomy session. Check serum EPO if you suspect primary polycythemia vera, because exogenous testosterone suppresses endogenous EPO and a paradoxically elevated EPO level points toward a myeloproliferative process.

Sleep Apnea Screening

Every man on TRT with hematocrit above 52 percent who has not been screened for obstructive sleep apnea should be referred for polysomnography or a validated home sleep test. The AASM guideline notes that untreated moderate-to-severe OSA raises hematocrit by 2 to 4 percentage points independently of testosterone [14]. Treating sleep apnea with CPAP sometimes resolves borderline erythrocytosis without any change to the testosterone regimen.

Long-Term Cardiovascular Implications of Unmanaged Erythrocytosis

Leaving hematocrit chronically elevated above 54 percent is not simply a laboratory abnormality to document and defer. The cardiovascular consequences are clinically meaningful.

Thrombotic Risk

Whole-blood viscosity rises steeply above a hematocrit of 50 percent. At 55 percent, viscosity is roughly 25 percent higher than at 45 percent, increasing shear stress on vessel walls and slowing venous flow. A meta-analysis in Arteriosclerosis, Thrombosis, and Vascular Biology that pooled data from 11 cohort studies found a hazard ratio of 1.72 (95% CI 1.31 to 2.26) for major adverse cardiovascular events in men with erythrocytosis compared to matched controls [15].

The TRT and CV Safety Data

The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, found that testosterone therapy in men with hypogonadism and high cardiovascular risk was non-inferior to placebo for MACE over a median 33-month follow-up [16]. However, the trial did report a statistically higher rate of venous thromboembolism (0.9 percent vs. 0.5 percent, P=0.03) in the testosterone arm, an effect that may be partly driven by uncorrected erythrocytosis in a subset of participants. This makes active hematocrit management a cardiovascular intervention, not just a hematologic formality.

Stroke and Cerebrovascular Risk

The American Heart Association notes that polycythemia (any cause) is an independent stroke risk factor when hematocrit exceeds 52 percent in men, particularly in the presence of other vascular risk factors like hypertension, diabetes, or atrial fibrillation [17]. TRT patients with these comorbidities deserve more aggressive hematocrit targets (below 52 percent rather than 54 percent).

Practical Guidance for Patients Who Want to Stay on TRT

Some patients are genuinely symptomatic without testosterone and cannot tolerate dose reductions without a significant drop in quality of life. This group is the hardest to manage.

Splitting Injections Further

Some clinicians move high-erythrocytosis responders from weekly to three-times-weekly microdose injections (e.g., 33 mg every Monday, Wednesday, Friday instead of 100 mg weekly). The flatter curve this produces can reduce peak EPO stimulation enough to keep hematocrit in the acceptable range. This requires patient willingness to inject more frequently, but subcutaneous delivery with a 27-gauge half-inch needle is comfortable for most men.

Subcutaneous Versus Intramuscular Delivery

Subcutaneous testosterone cypionate absorption is slower and produces lower peaks than intramuscular injection for the same dose. A pharmacokinetic study in Andrology (N=38) found that subcutaneous injection of 80 mg cypionate weekly produced a peak serum testosterone of 641 ng/dL versus 884 ng/dL for the same dose delivered intramuscularly, with no significant difference in trough levels [18]. Lower peaks mean less acute EPO stimulation per injection cycle.

The Role of Aspirin

Low-dose aspirin (81 mg daily) does not reduce hematocrit, but it reduces platelet aggregation and may partially offset the thrombotic risk associated with elevated viscosity. Evidence for this specific application is indirect, drawn from polycythemia vera management guidelines from the European LeukemiaNet, which recommend aspirin for all low-risk PV patients as standard practice [19]. Prescribing it in TRT-related erythrocytosis that cannot be fully corrected is a reasonable risk-reduction measure, provided no contraindications exist.